Skip to the story
GHK-Cu Backstory

GHK-Cu care questions need their own conversation.

The research explains why people are curious. Care raises different questions, including some that a long history in skincare simply can't answer.

Does GHK-Cu have FDA approval?

No GHK-Cu medicine has FDA approval. Skincare labels often call the copper complex Copper Tripeptide-1. That name doesn't tell us whether FDA has reviewed a medicine. FDA explains that cosmetics generally don't need approval before marketing. A cosmetic ingredient's presence on a shelf isn't an endorsement of an injection.

A drug identification number doesn't change that. FDA's drug-code directory explanation says a code doesn't mean approval. It's easy for an official-looking number to feel reassuring. It identifies a listing; it doesn't tell us that FDA has approved the medicine.

Where did the Category 2 entry go?

FDA dates the content of its safety page April 22, 2026. There, the injectable GHK-Cu entry appears under nominated but withdrawn; its earlier classification was Category 2. The nominators took back their request, but FDA kept its safety concerns. It doesn't date the individual withdrawal.

Taking back the nomination grants neither clearance nor compounding approval, and doesn't confer Category 1 status. For GHK-Cu used without injection, FDA has another entry in Category 1. Under the interim policy, FDA generally intends to hold off enforcement over Category 1 compounding that meets its guidance conditions. That's an enforcement policy, not a finding that a product is lawful or approved. The injectable entry sits outside it.

A clinician's decision doesn't add a missing human trial.

What worries FDA about injections?

FDA says the immune system could react against injectable GHK-Cu products. Its concerns include peptide impurities and the possibility of clumping. There isn't much human safety information to judge that risk. The entry supplies no reaction rate, so it can't tell me what percentage of patients might be harmed.

Cream studies don't answer the injection question. Small skin trials can't rule out uncommon harms either. Without an FDA-approved GHK-Cu label, there isn't an FDA-reviewed set of pregnancy or interaction instructions to rely on. Missing information is a reason for uncertainty, not reassurance.

What does prescription review decide?

Promise Peptides offers prescription-only injectable GHK-Cu care at mypromise.com. The review is individual. A U.S.-licensed clinician decides on prescribing and can refuse care. Not everyone qualifies for a prescription. Its service accepts U.S. patients only; state limits and treatment restrictions still apply. These compounded preparations have no FDA approval. A prescription alone doesn't show that a preparation meets every regulatory requirement.

The conversation still needs the intended goal, evidence in humans and what remains unknown. Compounded drugs aren't FDA-approved, even with a prescription. The dosage chapter explains why published experiments don't supply a personal plan. This guide gives no medical advice or individual treatment recommendation.